Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Oct:53:188-198.
doi: 10.1016/j.clnu.2025.08.009. Epub 2025 Aug 12.

Diet strategies for maintaining substantial therapeutic weight loss: 78-week mixed methods randomised trial

Affiliations
Free article
Randomized Controlled Trial

Diet strategies for maintaining substantial therapeutic weight loss: 78-week mixed methods randomised trial

Naomi Brosnahan et al. Clin Nutr. 2025 Oct.
Free article

Abstract

Background and aim: Formula low-energy diets (LED), used intermittently, may assist long-term weight-loss maintenance (WLM). This study compared total diet replacement 2 days/week (5:2TDR) and once-daily meal-replacements (DMR), delivered within a structured WLM programme.

Methods: A 78-week randomised trial was conducted in 63 individuals (75 % female, BMI 23-61 kg/m2), recruited between 12/04/2016 to 05/06/2018, after documented mean (SD) intentional weight-loss >8 kg, achieved using LED, behavioural programmes, or pharmacotherapy. Participants who had received anti-obesity medications were either weight stable or regaining after drug withdrawal. The primary outcome was weight change at 26-weeks following randomisation. Six dietitians and 25/63 (40 %) participants completed qualitative interviews at 26-weeks. Between-group differences were assessed using repeated ANCOVA adjusting for baseline values applying Intention-to-Treat, Per-Protocol, and As-Treated methods.

Results: At 26-weeks, 32/33 (97 %) randomised to 5:2TDR, and 29/30 (97 %) randomised to DMR, provided data. Four participants took pre-existing pharmacotherapy (n = 3 orlistat up to 78-weeks and n = 1 liraglutide up to 52-weeks). Mean (SD) pre-study weight-losses were similar between groups: 5:2TDR -15·0 (6·9) kg, DMR -18·8 (9·3) kg, p = 0.056. After 26-weeks WLM, intention-to-treat analysis found further weight-loss -0·9 kg (95 %CI -2·9, 1·5 kg) with 5:2TDR and regain with DMR 3·5 kg (95 %CI 1·3,5·5 kg); between-group difference -4·4 kg (95 %CI -7·3,-1·6 kg), p = 0·005. Maintained weight-losses at 26-weeks from pre-study start of weight loss were -15·8 (9·5) kg with 5:2TDR, -15·2 (10·5) kg with DMR, p = 0·977. Similar results were observed in the per protocol and as treated analyses. Both groups maintained weight losses >15 kg below baseline at 26, 52 and 78-weeks. Results were similar excluding those taking weight loss medications. Both interventions were well accepted. Dietitians successfully adapted LED interventions to overcome social/environmental challenges experienced by participants.

Conclusions: Structured dietary WLM is well accepted and can prevent weight regain after substantial loss, including after glucagon-like peptide-1 agonist withdrawal, and can maintain >15 kg loss up to 78-weeks TRIAL REGISTRATION: Clinicaltrials.gov: identifier NCT02683798.

Keywords: Glucagon-like peptide 1; Health; Meal replacements; Nutrition; Obesity; Weight loss maintenance.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest NB is currently employed by Counterweight Ltd and reports shareholdings from Counterweight Ltd. NB has also received funding of PhD fees and conference expenses from Cambridge Weight Plan and personal fees for freelance work for the British Dietetic Association. MEJL reports personal lecturing and consultancy fees from Novo Nordisk, Merck, Boehringer Ingleheim and Eli Lilly, and provides medical consultancy to Counterweight Ltd, with fees paid to the University of Glasgow. MEJL reports departmental funding from Cambridge Weight Plan, outside the submitted work. HR was previously employed by Counterweight Ltd. and has shareholdings from Counterweight Ltd. GT reports funding from Cambridge Weight Plan for PhD fees, conference expenses and departmental research, outside of the submitted work. WL reports conference expenses from Cambridge Weight Plan. ARL was previously employed by Cambridge Weight Plan. ARL is currently the chairman of Total Diet Meal Replacement Europe group. All other authors report no conflict of interest.

Publication types

Substances

Associated data